Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Parkinson's Foundation PD GENEration Genetic Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04994015
Recruitment Status : Recruiting
First Posted : August 6, 2021
Last Update Posted : August 24, 2021
Indiana University
Fulgent Genetics
Parkinson's Study Group
Information provided by (Responsible Party):
Parkinson's Foundation

Brief Summary:
Development of a central repository for PD-related genomic data for future research.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Device: Lab Assay for seven genetic variants for Parkinson's Disease Not Applicable

Detailed Description:
The purpose of this study is to develop a central repository for PD-related genomic data by individuals who consent to deposit their data and bank their residual DNA obtained through clinical genetic testing for future research use.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15000 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: All participants will undergo genetic counseling service post-genetic testing either locally or through central services.
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Parkinson's Foundation PD GENEration Genetic Registry
Actual Study Start Date : December 20, 2020
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : June 1, 2025

Resource links provided by the National Library of Medicine

Intervention Details:
  • Device: Lab Assay for seven genetic variants for Parkinson's Disease
    Counseling provided to participant by site clinician/physician/genetic counselor.

Primary Outcome Measures :
  1. Prevalence of Parkinson's related genetic mutations in an convenience cohort [ Time Frame: 6 months ]
    Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.

  2. Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling [ Time Frame: 6 months ]
    People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Study Population 1: PWP (open for recruitment)

    1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
    2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
    3. Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
    4. Able to perform study activities (including completion of either online, in-person or paper surveys).

Study Population 2: People at risk of developing PD (not open for recruitment)

1. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.

Exclusion Criteria:

  1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
  2. Individuals who have received a blood transfusion within the past 3 months.
  3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.
  4. Individuals who have had a bone marrow transplant within the past 5 years.
  5. Under the age of 18

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04994015

Layout table for location contacts
Contact: Kamalini Ghosh, MS 1-800-473-4636

Layout table for location information
United States, Colorado
University of Colorado Recruiting
Denver, Colorado, United States, 80045
Contact: Robbie Cummins   
Principal Investigator: Jeanne Feuerstein, MD         
United States, Florida
Aventura Neurologists-Visionary Investigators Network Recruiting
Aventura, Florida, United States, 33180
Contact: Jonathan Palmquist   
Principal Investigator: Julie Schwartzbard, MD         
United States, Georgia
Morehouse Healthcare Not yet recruiting
Atlanta, Georgia, United States, 30310
Contact: Sherline Sauveur   
Principal Investigator: Chantale Branson, MD         
United States, Massachusetts
St. Elizabeth's Medical Center Recruiting
Boston, Massachusetts, United States, 02136
Contact: Kaitlyn Ramsey   
Principal Investigator: Eleni Okeanis Vaou, MD         
Beth Israel Deaconess Medical Center (BIDMC) Recruiting
Boston, Massachusetts, United States, 02215
Contact: Hannah Babcock   
Principal Investigator: David Simon, MD         
United States, Washington
Inland Northwest Research Recruiting
Spokane, Washington, United States, 99202
Contact: Melissa Bixby Sanchez, MS   
Principal Investigator: Jason Aldred, MD         
Sponsors and Collaborators
Parkinson's Foundation
Indiana University
Fulgent Genetics
Parkinson's Study Group
Layout table for investigator information
Principal Investigator: James Beck, PhD Parkinson's Foundation
  Study Documents (Full-Text)

Documents provided by Parkinson's Foundation:
Informed Consent Form  [PDF] April 26, 2021

Layout table for additonal information
Responsible Party: Parkinson's Foundation Identifier: NCT04994015    
Other Study ID Numbers: PDGENE-PF
First Posted: August 6, 2021    Key Record Dates
Last Update Posted: August 24, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases